In Brief: Pharmacia & Upjohn
Executive Summary
Pharmacia & Upjohn: Delarvirdine expanded access program for non-nucleoside reverse transcriptase inhibitor for HIV infection has begun, firm announces. The expanded access program is open to HIV-1 positive patients 13 and older with CD4 counts below 300. The patients must be failing other therapies and receiving at least one other antiretroviral agent. An NDA for accelerated approval of Rescriptor is planned for "the next few months," Pharmacia & Upjohn said...